

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 15/28, 15/22, 15/44, 25/00	A1	(11) International Publication Number: WO 97/38737 (43) International Publication Date: 23 October 1997 (23.10.97)
(21) International Application Number: PCT/US97/06242 (22) International Filing Date: 16 April 1997 (16.04.97) (30) Priority Data: 08/633,272 16 April 1996 (16.04.96) US (71) Applicant: EASTMAN CHEMICAL COMPANY [US/US]; 100 North Eastman Road, Kingsport, TN 37660 (US). (72) Inventors: WU, Stephen, Hong-Wei; 1104 Meadow Lane, Kingsport, TN 37663 (US). HOPKINS, Warren, Kent; P.O. Box 367, Piney Flats, TN 37686 (US). (74) Agent: GRIFFIS, Andrew, B.; P.O. Box 511, Kingsport, TN 37662-5075 (US).		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: OXIDISED CELLULOSE AND VITAMIN E BLEND FOR TOPICAL HEMOSTATIC APPLICATIONS (57) Abstract The present invention relates to hemostatic composition comprising 1 to 90 weight percent of vitamin E or a derivative of vitamin E, 1 to 95 weight percent of oxidized cellulose, and 0.1 to 75 weight percent of water. The hemostatic composition may be formed into pellets, powder, paste, gum, gel, or liquid suitable for molding to conform to the contours of a wound.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

OXIDIZED CELLULOSE AND VITAMIN E BLEND
FOR TOPICAL HEMOSTATIC APPLICATIONS

Field of the Invention

5 The present invention relates to a hemostatic composition comprising 1 to 90 weight percent of vitamin E or a derivative of vitamin E, 1 to 95 weight percent of oxidized cellulose, and 0.1 to 75 weight percent of water.

10

Background of the Invention

 Four materials which are commonly used as hemostatic agents following surgery to control bleeding and oozing of fluids from wounds include thrombin, absorbable gelatin, microfibrillar collagen, and oxidized cellulose. Thrombin, commonly available as a powder derived from bovine sources, is a very effective clotting agent, but it may cause allergic reactions in sensitive individuals. Absorbable gelatin, available as sponges, packs, dental packs, or prostatectomy cones, is capable of absorbing and holding many times its weight of whole blood, and is absorbed completely by the body within four to six weeks. However, its use in the presence of infection is not recommended because it may form a nidus of infection and abscess formation.

 Microfibrillar collagen is an absorbable topical hemostatic agent prepared as a dry sterile, fibrous, water insoluble, partial hydrochloric acid salt of purified bovine corium collagen. While microfibrillar collagen does not generally initiate wound infections, it may promote infection, including abscess formation, and as an animal product, may promote allergic or foreign body reactions.

 Oxidized cellulose, is available under the trade name Oxycel™ from Becton Dickinson Co. Oxidized

- 2 -

cellulose is soluble in, or swollen by, fluids from wounds, forming a sticky mass which adheres readily and stops bleeding or the oozing of fluids from open wounds or surgical incisions, and is eventually absorbed by the body. Oxidized cellulose shows bactericidal effect against a wide range of pathogenic microorganisms. In addition, the biocompatibility and biodegradability of oxidized cellulose in vivo has been studied by Singh et al, Biomater. Med. Devices Artif. Organs, 7(4), 495-512(1979); Pierce et al, J. Oral Pathol. (Denmark), 13(6), 661-70 (1984); Mattsson et al, Swed. Dent. J. (Sweden), 13(2), 57-62(1990); and Demitrijevich et al, Carbohydrate Res 198(2), 331-41 (1990). The studies concluded that neither oxidized cellulose nor its degradation products are detrimental to either the healing process or the organism in general.

Oxidized cellulose is only available in solid forms such as pads, pladgets, or strips which, though soluble in mild bases, are not soluble in water. Oxidized cellulose does not form a paste in contact with water alone and it is reported that the hemostatic action is reduced by moistening with water or saline.

U.S. Patent No. 2,642,375 discloses a hemostatic composition comprising polyethylene glycol, of average molecular weight approx. 1500, and finely divided oxidized cellulose intimately mixed together.

European Patent App. 216,378 discloses hemostatic material based on fibrous particles of carboxycellulose and its alkali or calcium salts, and is characterized by the fact that the fibrous particles of the hemostatic agent are bonded physically or physico-chemically with particles of an adhesive to form a spatially crosslinked structure.

DE 2,852,319 discloses an absorbable, semisolid, hemostatic mass for use in prevention of bone

- 3 -

hemorrhages which contains a mixture of fibrin and collagen powder in a water-soluble, biotolerable foundation, and an adhesive selected from polyglucoside, gelatin, polyvinylpyrrolidone, cellulose esters, oxidized cellulose, and water-soluble starch or sugars.

Summary of the Invention

The topical hemostatic composition of the present invention can be used in the form of pellets, powder, paste, gum, gel, or liquid which can be spread over a wound, or molded into a shape which conforms to the contours of the wound. The topical hemostatic composition comprises:

- (A) 1 to 90 weight percent of vitamin E or a derivative of vitamin E;
- (B) 1 to 95 weight percent of oxidized cellulose; and
- (C) 0.1 to 75 weight percent water, wherein the weight percents are based on the total weight of the hemostatic composition.

Brief Description of the Drawings

The invention will be more fully understood and further advantages will become apparent when reference is made to the following detailed description of the invention and the accompanying drawings in which:

FIG. 1 is a photograph of an exposed rat liver containing three incisions. Incision 2 was untreated. Incision 4 was treated with a hemostatic composition containing 42 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 58 weight percent of oxidized cellulose, and about 0.1 weight percent of water in the form of a pellet. Incision 6 was treated with a hemostatic composition containing 37.5 weight

- 4 -

percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 51.8 weight percent of oxidized cellulose, and about 10.7 weight percent of water in the form of a paste.

5

FIG. 2 is a photograph of a pool of fresh blood with a hemostatic composition 8 containing 42 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 58 weight percent of oxidized cellulose, and about 0.1
10 weight percent of water in the form of a pellet.

FIG. 3 is a photograph of freshly cut bone of an animal. Sections 10, 14, and 18 were untreated. Section 12 was treated with a commercial bone wax. Section 16 was
15 treated with a hemostatic composition in malleable form containing 46.4 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 42.0 weight percent of oxidized cellulose, and about 11.6 weight percent of water. Section 20 was treated with a sterilized
20 hemostatic composition in malleable form containing 46.4 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 42.0 weight percent of oxidized cellulose, and about 11.6 weight percent of water.

FIG. 4 is a photograph of freshly cut bone of an animal to which an anticoagulant had been administered. Sections 22, 26, and 30 were untreated. Section 24 was treated with a commercial bone wax. Section 28 was treated with a hemostatic composition in malleable form
30 containing 46.4 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 42.0 weight percent of oxidized cellulose, and about 11.6 weight percent of water. Section 32 was treated with a sterilized hemostatic composition in malleable form containing 46.4
35 weight percent of d- α -tocopheryl polyethylene glycol

- 5 -

1000 succinate, 42.0 weight percent of oxidized cellulose, and about 11.6 weight percent of water.

Description of the Invention

5 The first component, component (A), of the topical hemostatic composition is vitamin E. As used herein, the term "vitamin E" refers to α , β , γ , and δ -tocopherol and their derivatives. The vitamin E may also be a combination of α , β , γ , and δ -tocopherols. The α -form
10 occurs naturally as the d-isomer known as d- α -tocopherol (d-2,5,7,8-tetramethyl-2-(4',8'12'-trimethyltridecyl)-6-chroman-
15 ol). Other forms of vitamin E which can be used include: d- α -tocopheryl acetate, d- α -tocopheryl succinate, d- α -tocopheryl nicotinate and d- α -tocopheryl
20 linoleate. Also the corresponding dl forms may be used which include: dl- α -tocopherol, dl- α -tocopheryl acetate, dl- α -tocopheryl succinate, dl- α -tocopheryl nicotinate and dl- α -tocopheryl linoleate and their derivatives. The vitamin E is present in an amount ranging from 1 to
25 90 weight percent, preferably 20 to 80 weight percent of the total topical hemostatic composition.

 An especially preferred vitamin E derivative is d- α -tocopheryl polyethylene glycol 1000 succinate (TPGS, a water-soluble vitamin E form with surfactant activity.
25 TPGS is prepared by the esterification of vitamin E succinate with polyethylene glycol wherein the polyethylene glycol has a number average molecular weight of 300 to 6000, preferably 1000. TPGS has a hydrophilic lipophilic balance of 15-19, and acts as an
30 emulsifier for lipophilic substances, including drugs. Moreover, the addition of TPGS to a drug dosage may enhance the bioavailability of the drug. TPGS is commercially available from Eastman Chemical Company.

 The second component, component (B), of the topical
35 hemostatic composition is oxidized cellulose. Oxidized

- 6 -

cellulose refers to cellulose specifically oxidized and containing carboxylic groups. The preferred form of oxidized cellulose contains a carboxylic group in the C₆ carbon. Oxidized cellulose is available from Eastman
5 Chemical Company.

Oxidized cellulose has hemostatic properties and aids in stopping bleeding. In addition, oxidized cellulose may be degraded by enzymes of the carbohydrase system and thus it is biodegradable and part of it may
10 be absorbed in the tissue without adverse effects. The incorporation of oxidized cellulose in wounds is helpful in absorbing fluids and aids healing. The combination of oxidized cellulose and vitamin E and/or its derivatives, is particularly effective in helping
15 directly to stop bleeding, and indirectly aids healing by reducing and inflammation, itching and the severity of scars. The preferred range of oxidized cellulose in the composition is 5 to 90 weight percent based on the total topical hemostatic composition. If the amount of
20 oxidized cellulose is too low, the hemostatic effect of the resulting gel will be reduced.

The third component, component (C), of the topical hemostatic composition is water. Water may be distilled or tap water. Distilled water is preferred because it
25 is free of metals, odors, and microbes.

Optionally, the topical hemostatic compositions may include bioactive materials, growth factors, plasticizing agents, opacifiers, surfactants, fragrances, sunscreens, antifungals, antibiotics, insect
30 repellents, preservatives, emollients, humectants, antioxidants, thickeners, moisturizers, astringents, deodorants, as well as other compatible materials which may be desired to enhance the properties of the compositions. The optional ingredients may be present

- 7 -

in widely varying amounts depending upon the particular ingredients selected and the results desired.

Examples of suitable bioactive materials include the following: growth promoters, growth factors such as glucan, hyaluronic acid, antioxidants such as beta-carotene, pain relievers such as lidocaine, benzocaine, and bupivacaine; antibiotics such as penicillin, cephalosporin, vancomycin, and bacitracin; anti-bacterials such as sulfanilamide, sulfacetamide, sulfadiazine, and pyrimethamine; and vitamins and vitamin derivatives (in addition to vitamin E), such as vitamin A, vitamin D, vitamin C, thiamine, riboflavin, and niacin. Two or more bioactive materials may be used in the same topical hemostatic composition, provided the bioactive materials do not react adversely with each other.

The topical hemostatic compositions of the present invention may be applied to a wound located anywhere on the body where wound treatment is desired, by smoothing it over the wound. The topical hemostatic compositions may also be formed into pellets or a paste suitable for molding to conform to the contours of a wound or extruded, for example through an instrument used for laparoscopic surgery, directly onto a wound. The topical hemostatic compositions reduce inflammation, swelling, and itching, promote wound healing, and reduce scarring.

The topical hemostatic compositions of the present invention are prepared by mixing oxidized cellulose with vitamin E and water, and if desired, an effective amount of pharmaceutically active agents. Mixing of the ingredients may be done in any convenient manner, and will depend upon the properties of the bioactive material which is added in addition to the vitamin E and oxidized cellulose. For example, oxidized cellulose and

- 8 -

vitamin E may be ground together cryogenically with dry ice or another cooling agent such as liquid nitrogen to give a powder which may then be blended with the bioactive material. Alternatively, oxidized cellulose and the bioactive material may be added to molten vitamin E with thorough mixing, and the resulting mixture may be ground cryogenically to a powder. In either case, the powder may be readily formed into a convenient form for use, such as into pellets, paste, powder, or tablets.

The method for mixing the components will depend upon the characteristics and stability of any bioactive compound which is added to the oxidized cellulose-vitamin E mixture. The blend of vitamin E and oxidized cellulose may be mixed with water to give a paste of the desired consistency. Alternatively oxidized cellulose powder may be blended into a solution or gel form of vitamin E in water.

A particularly useful application for the topical hemostatic composition is in the form a paste which may be spread over or shaped to conform to the contours of a wound. In bone surgery, for example, broken or cut bones are frequently covered with a stiff "bone wax". The primary function of bone wax is to prevent bleeding from broken bone ends. The material used for this purpose at present, beeswax with isopropyl palmitate, is not absorbed by the body, and it does not completely prevent oozing of blood and other fluids from the break. In contrast, a waxy paste prepared using TPGS, oxidized cellulose and if desired, a small amount of water, is completely absorbed by the body as the bone heals.

In another embodiment of the invention, the proportions of vitamin E, oxidized cellulose, water, and bioactive ingredients are chosen so that the resulting thin paste or gel may be extruded, for example through

- 9 -

an instrument used for laparoscopic surgery, directly onto a wound.

The following examples are intended to illustrate, but not limit, the scope of this invention. All percentages in the examples are on a weight bases unless otherwise stated.

Example 1

This example illustrates the preparation of a hemostatic composition in the form of a powder suitable for topical application to wounds.

Oxidized cellulose powder (11.6 grams) was added to 8.4 grams of molten TPGS. The mixture contained at least 0.1 weight percent of water. The mixture was stirred until cool, blended thoroughly in a mortar and pestle, then ground with dry ice to produce a fine powder, which was dried in a vacuum desiccator.

Example 2

This example illustrates the preparation of a paste of TPGS and oxidized cellulose.

TPGS (800.8 grams) was heated to 85°C and 200.4 grams of boiling water was added slowly in small portions. The mixture was stirred vigorously and allowed to cool to room temperature to form a hard, clear gel. The gel (16.7 grams) was added in small portions to 12 grams of oxidized cellulose powder, with grinding in a mortar and pestle after each addition. The resulting mass was kneaded to complete homogenization. The resulting paste exhibited the consistency of dough or putty, and may readily be shaped to conform to either internal or external wounds. Twelve samples of oxidized cellulose/TPGS/water mixtures were prepared and their characteristics were evaluated. The results are summarized in Table I.

TABLE I

Compositions and Characteristics of Oxidized
Cellulose/TPGS/Water Blends

Sample No.	TPGS/H ₂ O Gel Composition	Composition (g) Oxycell/ (TPGS/H ₂ O Gel)	Composition (g)		Composition (%)		Characteristics
			Oxycell/ TPGS/H ₂ O	TPGS/H ₂ O	Oxycell/ TPGS/H ₂ O	TPGS/H ₂ O	
1	90/10	8.04/(09.03)	8.04/08.37/00.93	46.03/48.3/5.36			Malleable/Staff
2	80/20	8.00/(11.04)	8.00/08.83/02.20	42.00/46.4/11.6			Malleable
3	60/40	8.02/(19.45)	8.02/11.67/07.78	29.02/42.5/28.3			Waxy, Pliable Gum
4	40/60	8.01/(18.47)	8.01/07.39/11.08	30.02/27.9/41.8			Gel
5	30/70	8.00/(24.64)	8.00/07.39/17.25	24.05/22.6/52.8			Gel-Wet Dough Consistency
6	20/80	8.00/(36.09)	8.00/07.38/29.05	17.08/16.4/65.7			Thick Liquid
7	90/10	8.00/(36.41)	8.00/32.77/03.64	18.01/73.8/8.20			Flowable Liquid
8	80/20	8.02/(41.11)	8.02/32.89/08.22	16.03/66.9/16.7			Waxy, Melts When Touched
9	60/40	4.02/(27.29)	4.02/16.37/10.92	12.09/52.3/34.9			Gel
10	40/60	2.01/(20.24)	2.01/08.10/12.14	09.03/36.4/54.6			Gel
11	30/70	2.00/(26.69)	2.00/08.01/18.68	06.97/27.9/65.1			Sticky Paste
12	20/80	2.02/(42.98)	2.02/08.60/34.38	04.48/19.1/76.4			Colloidal Solution

- 11 -

The results in Table I clearly indicate that all of the compositions were hemostatic. In addition, Sample Nos. 2, 3, and 4 exhibited the best handling properties in terms of ease of wound application.

5

Example 3

This example compares the effectiveness of the combination of TPGS with oxidized cellulose with that of either component alone, and with a control.

10 Operations were performed on four groups of ten rats each, as indicated in Table II. Identical incisions were made across the width of the kidneys, which were then treated with 0.2 grams of powdered hemostatic compositions as described in Table II. Total
15 blood loss and time until bleeding stopped are summarized in Table II.

TABLE II

	<u>Control</u>	<u>TPGS</u>	<u>Oxidized Cellulose</u>	<u>TPGS + Ox. Cell.</u>
Body Wt., g.	322±5	320±9	324±8	321±7
Blood Lost, g.	3.19±1.25	2.33±1.33	2.19±1.05	1.96±1.12
Bleed. Time, Sec.	364±170	266±143	276±88	174±52

- 13 -

The test results in Table II indicate that although there was notable reduction in both bleeding time and blood loss when either TPGS or oxidized cellulose was used alone, the effect of the combination of the two is statistically significant ($p < 0.05$).

Example 4

Three incisions were made in a rat liver as shown in FIG. 1. Incision 2 was untreated. Extensive bleeding occurred at the untreated incision. Incision 4 was treated with a hemostatic composition containing 42 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 58 weight percent of oxidized cellulose, and about 0.1 weight percent of water in the form of a pellet. No bleeding occurred at incision 4. Incision 6 was treated with a hemostatic composition containing 37.5 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 51.8 weight percent of oxidized cellulose, and about 10.7 weight percent of water in the form of a paste. No bleeding occurred at incision 6.

Example 5

A hemostatic composition containing 42 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 58 weight percent of oxidized cellulose, and about 0.1 weight percent of water in the form of a pellet was placed into a pool of fresh blood as shown in Fig. 2. Clotting occurred at the point of contact of the blood with the pellet and, to some extent, on the surface of the pool. There was no massive clotting of the entire pool of blood.

Example 6

A bone was cut as shown in Fig. 3. Sections 10, 14, and 18 were untreated. Massive bleeding occurred at

- 14 -

the untreated portion of bone. Section 12 was treated with a commercial bone wax. The bone wax allowed blood to ooze through the coating of bone wax. Section 16 was treated with a hemostatic composition in malleable form containing 46.4 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 42.0 weight percent of oxidized cellulose, and about 11.6 weight percent of water. Section 20 was treated with a sterilized hemostatic composition heated in an autoclave at 115°C-120°C for about 30 minutes. The hemostatic composition in malleable form contained 46.4 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 42.0 weight percent of oxidized cellulose, and about 11.6 weight percent of water. The sections covered with the topical hemostatic compositions showed no bleeding.

Example 7

This example is similar to Example 6, except that the animal had been treated with an anticoagulant, which retards clotting.

A bone was cut as shown in Fig. 4. Sections 22, 26, and 30 were untreated. Massive bleeding occurred at the untreated portion of bone. Section 24 was treated with a commercial bone wax. The bone wax allowed blood to ooze through the coating of bone wax. Section 28 was treated with a hemostatic composition in malleable form containing 46.4 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 42.0 weight percent of oxidized cellulose, and about 11.6 weight percent of water. Essentially no bleeding occurred at Section 28. Section 32 was treated with a sterilized hemostatic composition heated in an autoclave at 115°C-120°C for about 30 minutes. The hemostatic composition in malleable form contained 46.4 weight percent of d- α -tocopheryl polyethylene glycol 1000 succinate, 42.0

- 15 -

weight percent of oxidized cellulose, and about 11.6 weight percent of water. No bleeding occurred at Section 32.

- 16 -

WHAT IS CLAIMED IS:

1. A topical hemostatic composition comprising:
 - (A) 1 to 90 weight percent of vitamin E or a derivative of vitamin E;
 - 5 (B) 1 to 95 weight percent of oxidized cellulose; and
 - (C) 0.1 to 75 weight percent water, wherein the weight percents are based on the total weight of the hemostatic composition.
- 10 2. The topical hemostatic composition according to Claim 1 wherein (A) is 1 to 90 weight percent of a polyethylene glycol ester of vitamin E succinate.
- 15 3. The topical hemostatic composition according to Claim 1 wherein the vitamin E is selected from the group consisting of α , β , γ , and δ -tocopherol, and combinations thereof.
- 20 4. The topical hemostatic composition according to Claim 3 wherein the vitamin E is selected from the group consisting of d- α -tocopherol, d- α -tocopheryl acetate, d- α -tocopheryl succinate, d- α -tocopheryl nicotinate, d- α -tocopheryl linoleate, and
- 25 combinations thereof.
5. The topical hemostatic composition according to Claim 3 wherein the vitamin E is selected from the group consisting of dl- α -tocopherol, dl- α -
- 30 tocopheryl acetate, dl- α -tocopheryl succinate, dl- α -tocopheryl nicotinate, dl- α -tocopheryl linoleate, and combinations thereof.

- 17 -

6. The topical hemostatic composition according to Claim 1 which additionally contains at least one bioactive material.
- 5 7. The topical hemostatic composition according to Claim 6 wherein the bioactive material is selected from the group consisting of pain relievers, growth promoters, growth factors, antibiotics, anti-bacterials, vitamins and vitamin derivatives, and
10 combinations thereof.
8. The topical hemostatic composition according to Claim 7 wherein the bioactive material is selected from the group consisting of glucan, hyaluronic
15 acid, lidocaine, benzocaine, bupivacaine, penicillin, cephalosporin, vancomycin, bacitracin, sulfanilamide, sulfacetamide, sulfadiazine, pyrimethamine, vitamin A, vitamin D, vitamin C, thiamine, riboflavin, niacin, beta-carotene, and
20 combinations thereof.
9. The topical hemostatic composition according to Claim 8 wherein the bioactive material is selected from the group consisting of glucan, hyaluronic
25 acid, and beta-carotene.

1/4



Fig.1




Fig.2



Fig. 3



Fig.4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/06242

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L15/28 A61L15/22 A61L15/44 A61L25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 5 593 682 A (PAPAS ANDREAS M ET AL) 14 January 1997 see the whole document ---	1-9
A	EP 0 637 450 A (COLLAGEN CORP) 8 February 1995 see column 10, line 10 - line 57 see column 11, line 1 - line 18; claims ---	1-9
A	WO 92 13531 A (EASTMAN KODAK CO) 20 August 1992 see claims ---	1-9
A	EP 0 262 890 A (JOHNSON & JOHNSON MEDICAL) 6 April 1988 see claims ---	1-9
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

4 August 1997

Date of mailing of the international search report

12-08-1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/US 97/06242

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 659 440 A (JOHNSON & JOHNSON MEDICAL) 28 June 1995 see claims; examples 1-11 ---	1-9
A	EP 0 437 095 A (JOHNSON & JOHNSON MEDICAL) 17 July 1991 ---	
A	GB 1 006 606 A (FMC CORP.) 6 October 1965 see claims -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/06242

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5593682 A	14-01-97	NONE	
EP 0637450 A	08-02-95	CA 2103938 A JP 7089867 A	05-02-95 04-04-95
WO 9213531 A	20-08-92	US 5179122 A CA 2079325 A,C EP 0524308 A	12-01-93 12-08-92 27-01-93
EP 0262890 A	06-04-88	US 4840626 A AU 602726 B AU 7902687 A CA 1300022 A DE 3788404 D DE 3788404 T ES 2047493 T IE 63282 B JP 2563110 B JP 63102752 A KR 9513460 B	20-06-89 25-10-90 31-03-88 05-05-92 20-01-94 05-05-94 01-03-94 05-04-95 11-12-96 07-05-88 08-11-95
EP 0659440 A	28-06-95	AU 677118 B AU 8171894 A BR 9405232 A CA 2138850 A CN 1109756 A CZ 9403245 A DE 659440 T ES 2080034 T FI 946038 A HU 71587 A JP 7255830 A NO 944986 A PL 306475 A US 5484913 A ZA 9410283 A	10-04-97 29-06-95 01-08-95 24-06-95 11-10-95 18-10-95 10-10-96 01-02-96 24-06-95 28-12-95 09-10-95 26-06-95 26-06-95 16-01-96 24-06-96
EP 0437095 A	17-07-91	AU 639288 B CA 2033046 A GR 91100013 A	22-07-93 13-07-91 25-06-92

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/US 97/06242

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0437095 A		IN 171160 A	08-08-92
		JP 6199903 A	19-07-94
		US 5134229 A	28-07-92

GB 1006606 A		NONE	
